摘要
目的:观察卡瑞利珠单抗联合TP化疗方案治疗口腔癌患者的效果。方法:选取2020年1月至2024年7月该院收治的78例口腔癌患者进行前瞻性研究,按随机数字表法将其分为对照组与研究组各39例。对照组采用TP化疗方案治疗,研究组在对照组基础上联合注射用卡瑞利珠单抗治疗。比较两组临床疗效,治疗前后肿瘤标志物[神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)、糖类抗原19-9(CA19-9)]、T细胞亚群指标(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平,以及不良反应发生率。结果:研究组客观缓解率、疾病控制率均高于对照组,差异有统计学意义(P<0.05);治疗后,两组NSE、CEA、CA19-9水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平均低于治疗前,但研究组高于对照组,两组CD8^(+)水平均高于治疗前,但研究组低于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡瑞利珠单抗联合TP化疗方案治疗口腔癌患者可提高临床疗效,降低肿瘤标志物水平,改善T细胞亚群指标水平,其效果优于单纯TP化疗方案治疗。
Objective:To observe effects of Carrellizumab combined with TP chemotherapy in treatment of patients with oral cancer.Methods:A prospective study was conducted on 78 patients with oral cancer admitted to this hospital from January 2020 to July 2024.According to the random number table method,they were divided into control group and study group,39 cases in each group.The control group was treated with TP chemotherapy regimen,while the study group was treated with Carrellizumab for injection on the basis of that of the control group.The clinical efficacy,the levels of tumor markers[neuron-specific enolase(NSE),carcinoembryonic antigen(CEA),carbohydrate antigen 19-9(CA19-9)]and T cell subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate and disease control rate of the study group were higher than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of NSE,CEA and CA19-9 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CD4^(+)and CD4^(+)/CD8^(+)in the two groups were lower than those before the treatment,but those in the study group were higher than those in the control group;the levels of CD8^(+)in the two groups were higher than those before the treatment,but that in the study group was lower than that in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Carrellizumab combined with TP chemotherapy in the treatment of the patients with oral cancer can improve the clinical efficacy,reduce the levels of tumor markers,and improve the levels of T cell subsets.Moreover,it is superior to TP chemotherapy.
作者
程显林
赵科
尹鑫海
CHENG Xianlin;ZHAO Ke;YIN Xinhai(Department of Oral and Maxillofacial Surgery of Guizhou Provincial People’s Hospital,Guiyang 550001 Guizhou,China)
出处
《中国民康医学》
2025年第11期54-56,60,共4页
Medical Journal of Chinese People’s Health
